|
Ajanta Pharma, a Rs. 4,600 crore plus pharma major, has registered satisfactory financial performance during the second quarter ended September 2025 and the company management declared hefty interim dividend of Rs. 28 per share of face value of Rs. 2 each for the year 2025-26. Its revenue increased by 14.1 per cent to Rs. 1,354 crore from Rs. 1,187 crore in the corresponding quarter of last year. Its net profit moved up by 20.4 per cent to Rs. 260 crore from Rs. 216 crore with EPS moved up to Rs. 20.83 from Rs. 17.27. Currently, Ajanta Pharma scrip is moving around Rs. 2,600 on BSE as against 52-week high of Rs. 3,147 and low of Rs, 2,022.
Ajanta Pharma has presence in 30 countries including US, Asia, Africa and India. Its sales in India increased by 11.9 per cent to Rs. 432 crore during the second quarter ended September 2025 from Rs. 386 crore in the last period. Its US sales moved up strongly by 48 per cent to Rs. 343 crore from Rs. 232 crore. However, its sales in Asia improved only by 4.7 per cent to Rs. 310 crore from Rs. 296 crore and that in Africa increased only 3.8 per cent to Rs. 221 crore from Rs. 213 crore.
Its R&D expenditure increased to Rs. 63 crore from Rs. 57 crore and currently its 54 ANDAs active. The company has pending approval of 22 ANDAs. Its 50 products are on shelf and it launched three new products during the quarter under review. The company is planning to file 8 to 12 ANDAs with the help of its seven manufacturing plants.
For the first half ended September 2025, Ajanta Pharma revenues increased by 14 per cent to Rs. 2,656 crore from Rs. 2,331 crore and net profit moved up by 11.7 per cent to Rs. 516 crore from Rs. 462 crore Its EBITDA improved to Rs. 679 crore from Rs. 642 crore. The R&D expenditure up by 10.2 per cent to Rs. 119 crore from Rs. 108 crore. Ajanta Pharma’s US sales during the first half went up by 42 per cent to Rs. 653 crore from Rs. 460 crore and domestic sales moved up by 13.8 per cent to Rs. 841 crore from Rs. 739 crore.
|